Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.75 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.59 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 7/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.47 |
| ▸ | WDR5 | P61964 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3792582 | 0.94 | CXCR4 (0.79) | CXCR4APOBEC3AAPOBEC3GADRA2AADRA2B | |
| SCHEMBL11133792 | 0.93 | CXCR4 (0.82) | CXCR4APOBEC3AAPOBEC3GADRA2AADRA2B | |
| SCHEMBL5831369 | 0.93 | CXCR4 (0.82) | CXCR4APOBEC3AAPOBEC3GADRA2AADRA2B | |
| SCHEMBL2493767 | 0.89 | CXCR4 (0.59) | CXCR4APOBEC3AAPOBEC3GADRA2AADRA2B | |
| SCHEMBL13512431 | 0.88 | — | — | |
| SCHEMBL17471912 | 0.86 | CXCR4 (0.66) | CXCR4APOBEC3AAPOBEC3GADRA2AADRA2B | |
| SCHEMBL12343968 | 0.84 | CXCR4 (0.62) | CXCR4APOBEC3AAPOBEC3GADRA2AADRA2B | |
| SCHEMBL5677296 | 0.83 | CXCR4 (0.79) | CXCR4APOBEC3AAPOBEC3GADRA2AADRA2B | |
| SCHEMBL17472339 | 0.83 | CXCR4 (0.72) | CXCR4APOBEC3AAPOBEC3GADRA2AADRA2B | |
| SCHEMBL13512420 | 0.81 | CXCR4 (0.70) | CXCR4APOBEC3AAPOBEC3GADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285310-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | ARES CAPITAL CORPORATION, AS AGENT | 2023-09-14 | — | — | US | disclosed |
| EP-3197885-B1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2020-11-18 | — | — | EP | disclosed |
| WO-2017210668-A1 | SUSTAINED RELEASE COMPOSITIONS OF KAPPA-OPIOID RECEPTOR AGONIST | JT PHARMACEUTICALS, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
| US-9731016-B2 | Tyrosine-based lipids for delivery of therapeutics | MARINA BIOTECH, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9682970-B2 | Fluorescent compounds and uses thereof | BIOTIUM, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160206739-A1 | TYROSINE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS | MARINA BIOTECH INC (US) | 2016-07-21 | — | — | US | disclosed |
| US-9339461-B2 | Arginine-based lipids for delivery of therapeutics | MARINA BIOTECH, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9314468-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| WO-2016048861-A2 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2016-03-31 | — | — | WO | disclosed |
| US-20160083369-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | NAT HEALTH RESEARCH INSTITUTES (TW) | 2016-03-24 | — | — | US | disclosed |
| US-7964601-B2 | Agonist or antgonist and binders and inversion of agonist | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964601-B2 | Agonist or antgonist and binders and inversion of agonist | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7807678-B2 | Peptidomimetics of biologically active metallopeptides | PALATIN TECHNOLOGIES, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807678-B2 | Peptidomimetics of biologically active metallopeptides | PALATIN TECHNOLOGIES, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7732451-B2 | Naphthalene-containing melanocortin receptor-specific small molecule | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732451-B2 | Naphthalene-containing melanocortin receptor-specific small molecule | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7456184-B2 | Melanocortin receptor-specific compounds | PALATIN TECHNOLOGIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456184-B2 | Melanocortin receptor-specific compounds | PALATIN TECHNOLOGIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080234289-A1 | Melanocortin Receptor-Specific Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234289-A1 | Melanocortin Receptor-Specific Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206739-A1 | TYROSINE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS | ABL1, LCK, ERBB2 | CXCR4 2358/4885APOBEC3A 2916/4885APOBEC3G 3019/4885 |
| US-20160083369-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | CXCL12, HPGDS, MCL1 | CXCR4 6/4885APOBEC3A 3826/4885APOBEC3G 3915/4885 |
| US-20080234289-A1 | Melanocortin Receptor-Specific Compounds | MC1R, MC3R, MC5R | CXCR4 221/4885APOBEC3A 4214/4885APOBEC3G 3972/4885 |
| US-20230285310-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | CFTR, TSLP, MTREX | CXCR4 1281/4885APOBEC3A 1965/4885APOBEC3G 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.